Biotechnology has evolved predominantly in response to a market need for technologies and approaches that can speed up drug development and reduce R&D costs. With technology in a constant state of change, transforming one industry after another in its wake no biotechnology company can afford to hang on to the status quo for long. But neither can it predict with assurance which promising piece of technology will pan out, spinning off tomorrow's hot new product. In A NEW Wave of Intrabiotech Alliances - A Company and Therapeutic Market Analysis, we have identified two basic models that best describe the new wave of intrabiotech agreements - a vertical (towards drug development) and a horizontal one (towards technology development for drug discovery or diagnostics). These alliances have the potential to shape the strategies and evolution of the biotechnology industry. Datamonitor analyzes the impact of these alliances on the therapeutic franchises of the partnering companies and the future of the specific technological platforms.
